ALLMedicine™ Bladder Cancer Center

May 7th, 2021 - Urothelial cancer is the second most common cancer, and cause of cancer death, related to the genitourinary tract. The goals of surveillance imaging after the treatment of urothelial cancer of the urinary bladder are to detect new or previously un...

May 7th, 2021 - There are many risk factors for bladder cancer. During an initial assessment of a patient with bladder cancer, a careful discussion and history assessment is important. Particular focus should include social history with details regarding occupati...

May 7th, 2021 - Recently completed studies provided high-resolution descriptions of the molecular biological characteristics of urothelial bladder cancers. Whole transcriptome messenger RNA expression profiling revealed that they can be grouped into basal and lum...

May 7th, 2021 - Radical cystectomy is curative in only approximately 50% of patients with muscle-invasive bladder cancer. Although perioperative radiotherapy has been tested with the intent of improving locoregional disease control, there currently is no role for...

May 7th, 2021 - Transurethral resection of bladder tumor remains the cornerstone of non-muscle invasive bladder cancer management, proper risk stratification, and appropriate selection of adjuvant therapy. A single, postoperative dose of intravesical chemotherapy...

May 7th, 2021 - Urothelial cancer is the second most common cancer, and cause of cancer death, related to the genitourinary tract. The goals of surveillance imaging after the treatment of urothelial cancer of the urinary bladder are to detect new or previously un...

May 27th, 2020 - Is maintenance therapy with an immune checkpoint inhibitor a good idea for patients with advanced bladder cancer who do not progress after initial chemotherapy?

May 27th, 2020 - Maintenance therapy with a PD-L1 immune checkpoint inhibitor improved overall survival (OS) for patients with advanced bladder cancer and stable disease following first-line chemotherapy, an interim analysis of a phase III trial found.

Feb 24th, 2020 - During the 2019 International Society of Urological Pathology Consultation Conference on Molecular Pathology of Urogenital Cancer, the Working Group on Bladder Cancer presented the current status and made recommendations on the diagnostic use of m...

Jan 28th, 2020 - Despite an increased use of neoadjuvant and adjuvant chemotherapy, the long-term survival rates after radical cystectomy or trimodal therapy (TMT) for muscle-invasive bladder cancer (MIBC) remain basically unchanged for decades. Detection and effe...

May 7th, 2021 - Urothelial cancer is the second most common cancer, and cause of cancer death, related to the genitourinary tract. The goals of surveillance imaging after the treatment of urothelial cancer of the urinary bladder are to detect new or previously un...

May 7th, 2021 - There are many risk factors for bladder cancer. During an initial assessment of a patient with bladder cancer, a careful discussion and history assessment is important. Particular focus should include social history with details regarding occupati...

May 7th, 2021 - Recently completed studies provided high-resolution descriptions of the molecular biological characteristics of urothelial bladder cancers. Whole transcriptome messenger RNA expression profiling revealed that they can be grouped into basal and lum...

May 7th, 2021 - Radical cystectomy is curative in only approximately 50% of patients with muscle-invasive bladder cancer. Although perioperative radiotherapy has been tested with the intent of improving locoregional disease control, there currently is no role for...

May 7th, 2021 - Transurethral resection of bladder tumor remains the cornerstone of non-muscle invasive bladder cancer management, proper risk stratification, and appropriate selection of adjuvant therapy. A single, postoperative dose of intravesical chemotherapy...

Apr 20th, 2021 - Patients with cancer face an increased risk of arterial thromboembolic events, including myocardial infarction (MI) and stroke, and for some that risk appears substantial, according to a new population-based study. For example, the 6-month inciden...

Mar 8th, 2021 - ZURICH (Reuters) - Roche on Monday joined AstraZeneca in withdrawing cancer immunotherapies from U.S. use for bladder cancer that has already been treated with platinum-based chemotherapy, after follow-up studies failed to meet goals. Basel-based ...

Feb 22nd, 2021 - After failing to improve overall survival in unresectable metastatic bladder cancer in a phase 3 trial, this indication will be withdrawn in the United States for the immunotherapy durvalumab (Imfinzi), AstraZeneca announced. The withdrawal does n...

Jan 31st, 2021 - The use of low-dose aspirin among older people shows no effect in reducing the incidence of certain cancer types. However, the treatment — particularly with frequency of at least three times a week — is associated with reductions in mortality in b...

Jan 26th, 2021 - My patient, a woman with metastatic bladder cancer who was about to move to a different part of the country, was perplexed: "Can't you just give me my records on a flash drive?" Unfortunately it wasn't that easy. Forms needed to be routed through ...